Significance of monitoring imatinib concentration in Gastrointestinal Stromal tumor patients

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter H. Xu
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors H. Xu, Z. Xu, L. Yang, D. Zhang, F. Li
  • The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, /

Abstract

Imatinib mesylate is a tyrosine kinase inhibitor used as first-line treatment in Philadelphia chromosome–positive chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Therapeutic drug monitoring (TDM) for imatinib has been suggested to improve efficacy, assess complication and evaluate drug–drug interactions in CML. However, little is known in the era of GIST.